Exenatide Extended-Release: A Once Weekly Treatment for Patients With Type 2 Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - New Zealand
doi 10.2147/dmso.s35331
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Exenatide Once-Weekly Injection for the Treatment of Type 2 Diabetes in Chinese Patients: Current Perspectives

Therapeutics and Clinical Risk Management
2015English

Once-Weekly Exenatide as Adjunct Treatment of Type 1 Diabetes Mellitus in Patients Receiving Continuous Subcutaneous Insulin Infusion Therapy

Canadian Journal of Diabetes
Internal MedicineEndocrinologyMetabolismMedicineDiabetes
2014English

Adherence to Liraglutide Once Daily or Exenatide Once Weekly Over a 12-Month Period Among Commercially Insured Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Dulaglutide: Third Once-Weekly GLP-1 Agonist for Type 2 Diabetes

Pharmacy Today
2014English

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK

Advances in Therapy
MedicinePharmacology
2020English

The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Journal of Diabetes Research
EndocrinologyMetabolismDiabetes
2019English

Patient Preference for Once-Weekly Dosing in Type 2 Diabetes Mellitus in Japan

Journal of Health Economics and Outcomes Research
2016English

Exenatide (Byetta) as a Novel Treatment Option for Type 2 Diabetes Mellitus

Baylor University Medical Center Proceedings
Medicine
2006English

Once-Weekly Albiglutide in the Management of Type 2 Diabetes: Patient Considerations

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy